| Revenue growth | 18% YoY growth in Q1FY27. |
|---|---|
| Margins | Adjusted EBITDA margin improved to 13.6% from 12.8%. |
| Demand visibility | Strong CDMO demand; expanding customer base to 926. |
| Management confidence | High; citing 14 consecutive quarters of growth. |
Growth
Generic Formulations CDMO grew 29% YoY; Exports surged 79%. Trade Generics declined 32% due to codeine product discontinuation.
Outlook
Plant-6 commercialization on track for H1FY27. Capex of ₹73 Cr in FY26 focused on OSD capacity expansion.
Risks
Trade Generics vertical faced headwinds from product discontinuation; non-cash ESOP expenses impacted reported margins.
Last quarter's promises, checked
Delivered
- Plant 6 commercialization by H1 FY27 → On track (= BEAT)
- Maintain ROCE/ROE above 25% → Sustained above 25% (= BEAT)
- Revenue growth outperforming IPM volume → 18% vs 3.4% (= BEAT)
Partly delivered
- Injectables scaling → Catching up but with earlier timeline lag (= PARTIAL)
Missed
- Trade Generics growth → -32% decline due to codeine exit (= MISS)
Investor Presentation filed with NSE, NSE: WINDLAS. Summary written with AI assistance from the document.
Windlas Biotech Ltd: key numbers
- Share price
- ₹1,029.00
- Market cap
- ₹2,160 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 32.5×Sector 47.4×
- Promoter holding
- 63.31%+1.41% QoQ
- FII holding
- 2.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Earnings Call Transcript: Key Takeaways
Windlas Biotech reported record quarterly revenue driven by 29% growth in CDMO vertical. Management focuses on operational excellence and capacity expansion via Plant 6 commercialization.
Windlas Biotech Results Update
Windlas Biotech reported Q1 FY27 revenue of Rs 248 crore, an 18% YoY growth. The release highlights an adjusted EBITDA of Rs 34 crore and PAT of Rs 25 crore.
Windlas Biotech Q1 FY27 Results: Net Profit ₹17.7 Cr, Up 0.0% YoY
Windlas Biotech Ltd reported revenue from operations of ₹248.1 Cr (+18.1% YoY) and net profit of ₹17.7 Cr (+0.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹17.7 Cr · +0.0% YoY
Windlas Biotech Board Meeting Date
Windlas Biotech Limited has scheduled a board meeting on August 10, 2026, to consider and approve its unaudited standalone financial results for the quarter ending June 30, 2026.
Windlas Biotech Annual General Meeting
Windlas Biotech Ltd held its 25th Annual General Meeting on July 23, 2026. Shareholders approved the financial statements and a final dividend of Rs. 6.30 per share.
Windlas Biotech Annual Report
Windlas Biotech Limited filed its Annual Report for the financial year 2025-26. The report highlights the company's operational performance and growth milestones.